Biomarin Pharmaceutical Inc(BMRN) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
September 10 at 7:30 PM ET (Korea 9/11 08:30)
Full metrics table
| Index | - | P/E | 176.62 | EPS (ttm) | 0.37 | Insider Own | 1.29% | Shs Outstand | 193.5M | Perf Week | -2.18% |
| Market Cap | 12.68B | Forward P/E | 9.83 | EPS next Y | 32.43% | Insider Trans | -1.47% | Shs Float | 191.1M | Perf Month | -5.81% |
| Enterprise Value | 16.02B | PEG | 0.15 | EPS next Q | 1.33 | Inst Own | 102.5% | Short Float | 5.34% | Perf Quarter | 16.63% |
| Income | 0.07B | P/S | 3.67 | EPS this Y | 179.54% | Inst Trans | 1.11% | Short Ratio | 5.22 | Perf Half Y | 8.6% |
| Sales | 3.46B | P/B | 2.01 | EPS next 5Y | 63.45% | ROA | 0.76% | Short Interest | 10.20M | Perf YTD | 10.23% |
| Book/sh | 32.66 | P/C | 14.51 | EPS past 3/5Y | 34.05% -16.79% | ROE | 1.18% | 52W High | -7.71% ($70.98) | Perf Year | 20.2% |
| Cash/sh | 4.52 | P/FCF | 17.18 | Sales past 3/5Y | 16.55% 11.97% | ROIC | 0.74% | 52W Low | 32.99% ($49.26) | Perf 3Y | -27.36% |
| Dividend Est. | - | EV/EBITDA | 20.22 | EPS Y/Y TTM | -89.03% | Gross Margin | 73.93% | Volatility(W/M) | 2.67% 2.52% | Perf 5Y | -15.99% |
| Dividend TTM | - | EV/Sales | 4.64 | Sales Y/Y TTM | 13.69% | Oper. Margin | 18.5% | ATR (14) | 1.82 | Perf 10Y | -30.33% |
| Dividend Ex-Date | - | Quick Ratio | 1.32 | EPS Q/Q | -81.28% | Profit Margin | 2.11% | RSI (14) | 52.23 | Recom | 1.6 |
| Dividend Gr. 3/5Y | - | Current Ratio | 2.39 | Sales Q/Q | 20.41% | SMA20 | -1.08% ($66.23) | Beta | 0.21 | Target Price | $91.48 |
| Payout | - | Debt/Eq | 0.67 | Earnings | 2026/8/6 | SMA50 | 4% ($62.99) | Rel Volume | 1.12 | Prev Close | $64.41 |
| Employees | 3221 | LT Debt/Eq | 0.56 | EPS/Sales Surpr. | 26.66% 6.19% | SMA200 | 12.89% ($58.03) | Avg Volume(3M) | 1.95M | Price | $65.51 |
| IPO | 1999/7/23 | Option/Short | Yes/Yes | Trades | 17771 | Volume | 2,182,422 | Change | 1.71% |
Company
BMRN is a Healthcare sector company, analyzed across 14 metrics on this page including P/E, EPS, dividends, RSI, and MACD.
A U.S. biopharmaceutical company that develops and sells treatments for rare genetic diseases, specializing in rare disease therapeutics. Because the patient population is small, drug prices tend to be high, and both sales of marketed products and pipeline performance drive earnings results.
Over the past 1 year, roughly in the middle
8% below its 1-year high.
BMRN has weak earning power
18.5% of revenue is kept as operating profit.
Tap to view numbers
Earnings are growing steadily
Earnings are expected to grow by +179.5% this year.
Tap to view numbers
The stock looks undervalued
Trading at 176.6 times earnings.
Tap to view numbers
Results have missed expectations
Frequently misses analyst estimates
Tap to view numbers
The outlook is positive
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Would have changed by -27.4% if bought 5 years ago.
Tap to view numbers
Dividends are hard to expect
This stock does not pay dividends
Ownership looks stable
Institutions hold 102.5%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
GNOM 0.04%
FBT 0.03%
ASD 0.03%
PBE 0.02%
INVN 0.02%It ranks #4 in the industry
Based on market cap of $13B.
BMRN $13B PER 176.6
VRTX $130B PER 29.9
REGN $82B PER 19.6
ARGX $62B PER 37.5
FAQ
What kind of company is BMRN?
BMRN belongs to the Healthcare sector and operates in the Biotechnology industry.
What is the market cap of BMRN?
The market cap of BMRN is approximately $12.7B, ranking 806 within its sector.
What is the P/E ratio of BMRN?
BMRN has a P/E ratio of approximately 176.6x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for BMRN?
BMRN has recorded a 52-week high of $70.98 and a low of $49.26.
